CJC-1295
Explore CJC-1295, including growth-hormone-releasing hormone research, limited human evidence, product-name ambiguity, and current FDA compounding concerns.
What Is CJC-1295?
CJC-1295 is a name used for several synthetic analogs related to growth-hormone-releasing hormone, or GHRH. Some versions incorporate a drug-affinity-complex component intended to prolong activity, while other materials marketed under the same name may differ in sequence or chemical form.
Small human studies evaluated particular CJC-1295 forms in healthy adults and reported increases in growth hormone and IGF-1. These short studies were not designed to establish treatment effectiveness for growth-hormone deficiency or broad wellness claims.
CJC-1295 is not an FDA-approved drug. Inconsistent naming and characterization make it especially important not to assume that research on one form applies to another.
What Has CJC-1295 Been Studied For?
CJC-1295-related substances have been studied for their effects on growth-hormone and IGF-1 concentrations. Available human trials were small, short, and primarily pharmacologic rather than trials demonstrating clinical benefit for a diagnosed disorder.
FDA concluded that available evidence does not establish effectiveness for treating growth-hormone deficiency and noted a lack of adequate clinical safety information across the evaluated forms.
Claims involving anti-aging, muscle gain, fat loss, recovery, or performance are not established by the available clinical evidence.
CJC-1295: Current Regulatory & Compounding Status
CJC-1295 is not FDA approved. FDA has proposed against adding multiple CJC-1295 forms to the 503A Bulks List, citing inconsistent naming and physicochemical characterization, limited clinical data, lack of effectiveness evidence, and possible safety concerns.
FDA also identifies potential immunogenicity and peptide-impurity concerns and reports serious adverse events associated with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.
Freedom does not present CJC-1295 as an available compounded therapy. Patients with suspected growth-hormone disorders should discuss established diagnostic pathways and FDA-approved treatment options with a qualified clinician.
CJC-1295 Status & Clinical Alternatives
-
Current Regulatory Status
Review CJC-1295 StatusCJC-1295 is not FDA approved. FDA has identified characterization, safety, and evidence concerns and has proposed against adding evaluated CJC-1295 forms to the 503A Bulks List.
-
FDA-Approved Clinical Alternatives
Talk to a PharmacistFDA-approved diagnostic and treatment options exist for defined growth-hormone disorders. A licensed prescriber can evaluate symptoms, laboratory findings, and appropriate alternatives.
CJC-1295 Frequently Asked Questions
Is CJC-1295 FDA approved?
No. CJC-1295 is not an FDA-approved drug.
Does Freedom compound CJC-1295?
Freedom does not present CJC-1295 as an available compounded therapy. FDA has identified significant characterization, safety, and evidence concerns.
Does Freedom sell BAre all products called CJC-1295 the same?C-157 products?
No. The name has been applied to multiple forms, including materials with and without a drug-affinity-complex component. Research on one form should not be generalized to another.
How does CJC-1295 work?
Published research has investigated BPC-157 in areas including gastrointestinal tissues, inflammatory processes, blood-vessel signaling, conCJC-1295-related substances are designed to act as GHRH analogs and have been studied for their effects on growth-hormone and IGF-1 concentrations.ective tissue, and tissue-repair mechanisms. Much of this evidence comes from laboratory and animal research.
Is there human research on CJC-1295?
Human evidence is limited compared with the amount of preclinical research. Experimental findingsLimited small, short-duration human pharmacology studies exist. FDA found no adequate evidence establishing effectiveness for treatment of growth-hormone deficiency.should not be assumed to demonstrate safety or effectiveness in people.
What safety concerns has FDA identified?
FDA cites potential immunogenicity, peptide impurities, inconsistent characterization, limited clinical safety data, increased heart rate, and a systemic vasodilatory reaction.
Does Freedom sell research-use-only CJC-1295?
No. Freedom Compounding Pharmacy serves patients and licensed healthcare providers and does not sell research-use-only peptides.
Questions About CJC-1295?
Freedom Compounding Pharmacy can help patients and licensed healthcare providers understand CJC-1295 research, FDA's current concerns, and established clinical alternatives.